Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial, Advancing Novel Neuroprotective Approach

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 trial of Lucid-MS, its lead drug candidate for multiple sclerosis (MS). The agreement transitions the program from planning into execution and marks a critical step in evaluating a treatment that takes a fundamentally different approach to MS.

Most existing MS therapies work by suppressing or modulating the immune system to reduce inflammatory attacks on the central nervous system. Lucid-MS is designed around a novel neuroprotective mechanism that targets demyelination—the loss of the protective myelin sheath that insulates nerve fibers—rather than solely altering immune activity. By focusing on preserving myelin, the drug aims to address a root cause of disability progression in MS, potentially offering benefits that complement or exceed those of current immunomodulatory treatments.

The selection of Thermo Fisher’s clinical research business, a leading global contract research organization with deep expertise in central nervous system and MS studies, underscores the scientific rigor intended for the Phase 2 trial. Thermo Fisher will provide operational and clinical support, helping to ensure the study is conducted efficiently and to the highest standards. For Quantum BioPharma, this partnership represents both validation of its platform and a practical pathway to generate the clinical data needed to advance Lucid-MS.

If successful, Lucid-MS could become a first-in-class therapy that shifts the treatment paradigm for MS, a chronic disease affecting millions worldwide. Current treatments often require long-term immune suppression, which carries risks of infection and other side effects. A neuroprotective approach could be used earlier or in combination with existing drugs, potentially slowing disability accumulation more effectively.

Investors and industry observers are likely to watch the trial’s progress closely, as positive results would not only boost Quantum BioPharma’s pipeline but also attract interest from larger pharmaceutical companies seeking novel MS assets. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, and social media distribution to help companies reach a broad audience of investors and journalists. For full terms of use and disclaimers, see https://www.InvestorWire.com/Disclaimer.